Ensitrelvir (fumarate)

Ensitrelvir is an orally bioavailable inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), also known as 3C-like protease (3CLpro), with an IC50 value of 0.013 µM. It is selective for Mpro over HIV-1 protease and the human proteases caspase-2, chymotrypsin, thrombin, and cathepsin B, -D, -G, and -L (IC50s = >100 µM for all). Ensitrelvir reduces the cytopathic effects of SARS-CoV-2 clinical isolates, including Alpha, Beta, Gamma, Delta, and Omicron strains, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), in Vero E6 cells expressing human transmembrane serine protease 2 (TMPRSS2, EC50s = 0.29-1.4 µM). Oral administration of ensitrelvir decreases lung viral titers in a mouse model of SARS-CoV-2 Gamma variant infection when administered at doses ranging from 2 to 32 mg/kg at the time of, and 12 hours after, infection.Formal Name: (6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4(1H,3H)-dione, (2E)-2-butenedioate. CAS Number: 2757470-18-9. Synonyms: S-217622. Molecular Formula: C22H17ClF3N9O2 . C4H4O4. Formula Weight: 647.9. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 10 mg/ml, DMSO: 10 mg/ml, Ethanol: insol, PBS (pH 7.2): insol. SMILES: O=C(N/1CC2=CC(F)=C(C=C2F)F)N(C(NC1=N/C3=CC4=CN(N=C4C=C3Cl)C)=O)CC5=NN(C=N5)C.O=C(/C=C/C(O)=O)O. InChi Code: InChI=1S/C22H17ClF3N9O2.C4H4O4/c1-32-7-12-4-18(13(23)5-17(12)30-32)28-20-29-21(36)35(9-19-27-10-33(2)31-19)22(37)34(20)8-11-3-15(25)16(26)6-14(11)24,5-3(6)1-2-4(7)8/h3-7,10H,8-9H2,1-2H3,(H,28,29,36),1-2H,(H,5,6)(H,7,8)/b,2-1+. InChi Key: FBOCUALVLIWPNQ-WLHGVMLRSA-N.